BioNTech Takes Aim at Keytruda as ASCO Data Deliver the Verdict on Pipeline Potential

BioNTech heads into ASCO with pivotal data for Pumitamig in lung cancer and Gotistobart in ovarian cancer, as stock lags behind pipeline momentum despite strong cash position.

BioNTech heads into the American Society of Clinical Oncology meeting with two late-stage candidates carrying outsized expectations — and a stock that has shrugged off months of clinical progress. The German biotech's shares closed Friday at €79.50, up 1.5 percent on the day but still roughly 15 percent below where they traded a month ago. The disconnect between pipeline momentum and market sentiment has rarely been starker.

The centerpiece of the ASCO presentation, scheduled for May 30, is an updated dataset from the pivotal phase 2/3 ROSETTA Lung-02 study. Pumitamig — a bispecific PD-L1/VEGF-A immunomodulator developed with Bristol Myers Squibb — is being tested against the gold-standard checkpoint inhibitor pembrolizumab (Merck's Keytruda) in first-line non-small cell lung cancer. The dose-optimization portion has already generated encouraging efficacy across PD-L1 expression levels and tumor histologies, and the forthcoming data cut will show whether that signal holds up in a head-to-head comparison. An oral rapid abstract session will present the results.

The second oral presentation covers Gotistobart, a CTLA-4 antibody partnered with OncoC4. Phase 2 data from the PRESERVE-004 trial in heavily pretreated platinum-resistant ovarian cancer showed durable responses and clinically meaningful overall survival when combined with pembrolizumab. The combination could open a chemotherapy-free option in a notoriously difficult-to-treat setting. That presentation also lands on May 30.

Beyond the two oral slots, BioNTech will showcase four "trial in progress" posters covering antibody-drug conjugates and novel combination regimens. The company now runs more than 25 phase 2 and phase 3 oncology studies, 13 of them in pivotal stages. It plans to launch six more phase 3 trials this year, pushing the total to 15, and expects to deliver seven late-stage data packages by the end of 2026.

Wall Street has taken notice, but the tone is measured. Bernstein initiated coverage with a Market Perform rating and a $96 price target, noting BioNTech's sturdy balance sheet — €16.8 billion in cash and securities as of March 31 — while flagging elevated approval risk for the pipeline. J.P. Morgan recently reaffirmed its Hold rating. The broader analyst consensus of 17 ratings stands at Buy, with an average price target of $125.45 — implying roughly 38 percent upside from current levels.

That cash pile is underwriting a hefty burn rate. First-quarter 2026 revenue came in at €118.1 million, while the net loss widened to €531.9 million. Research and development spending surged to €557.0 million, driven by Pumitamig and Gotistobart as well as costs from 2025 acquisitions and an intangible asset impairment. BioNTech is holding to a full-year revenue forecast of €2.0 billion to €2.3 billion (roughly $2.3 billion to $2.6 billion at current exchange rates), with adjusted R&D spending planned at €2.2 billion to €2.5 billion.

The stock's recent slide — a 30-day loss of about 15 percent — stands in sharp contrast to the clinical narrative. At €79.50, the shares are roughly 10 percent above the 52-week low of €72.50 but well below the 200-day moving average of €86.47. The relative strength index sits at 50.6, indicating no clear overbought or oversold condition. The selloff has lacked a single trigger, suggesting a market that is simply unwilling to price in pipeline potential until regulatory de-risking becomes visible.

That de-risking may now arrive. If Pumitamig convincingly matches or exceeds pembrolizumab in the updated ROSETTA Lung-02 analysis, the thesis around BioNTech's oncology pivot gains real weight. Gotistobart's showing in ovarian cancer could add a second independent proof point. Together, these data sets have the power to close the gap between the current share price and the analyst consensus — or widen it, if the results fall short. Either way, May 30 marks the moment BioNTech's pipeline moves from promise to proof.